{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:18:29Z","timestamp":1787242709387,"version":"build-2736575974"},"reference-count":51,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T00:00:00Z","timestamp":1729382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tisotumab vedotin (TV) holds promise for treating recurrence or metastatic cervical cancer (r\/mCC), with recent FDA approval for second\u2010line use in recurrent or metastatic cases. Our research aims to evaluate TV's efficacy and safety in these patients, focusing on overall survival (OS) and progression\u2010free survival (PFS) outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched five electronic databases in February 2024, retrieved articles, screened them based on inclusion and exclusion criteria, and assessed their quality. A meta\u2010analysis of the extracted data was performed and applied a random\u2010effects model for our analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search identified 86 articles, with six meeting the inclusion criteria. Meta\u2010analysis revealed 80.8% and 48.0% OS at 6 and 12\u2009months, and a 29.9% PFS at 6\u2009months. Combined treatment with carboplatin or pembrolizumab showed 33.0% PFS at 1\u2009year and 15.1% at 2\u2009years. The objective response rate (ORR) was 21.0%, reaching 43.3% with combined treatment. Confirmed disease control rate (CDCR) was 70.0% overall and in combination. The median duration of response (DOR) was 6.1\u2009months, increasing to 9.5\u2009months in combined treatment, with a consistent time to response (TTR) of 1.4\u2009months. Adverse events included ocular issues (conjunctivitis 30.3%, dry eye 18.7%) and common side effects (nausea 38.4%, epistaxis 35.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review and meta\u2010analysis highlights the potential of TV as a treatment option for r\/mCC patients. However, healthcare providers must communicate safety profiles and recommend prophylactic measures for optimal patient outcomes. Further studies, particularly assessing combination treatments, are needed to clarify TV's role in treatment algorithms and improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jog.16126","type":"journal-article","created":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T21:59:18Z","timestamp":1729461558000},"page":"2195-2210","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of tisotumab vedotin with cervical cancers: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0239-5814","authenticated-orcid":false,"given":"Muhammed Edib","family":"Mokresh","sequence":"first","affiliation":[{"name":"Hamidiye International School of Medicine University of Health Sciences  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Alomari","sequence":"additional","affiliation":[{"name":"Hamidiye International School of Medicine University of Health Sciences  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Varda","sequence":"additional","affiliation":[{"name":"Hamidiye International School of Medicine University of Health Sciences  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goncagul","family":"Akdag","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi Kirdar City Hospital Health Science University  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Odabas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Kartal Dr. L\u00fctfi Kirdar City Hospital Health Science University  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,10,20]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30482-6"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32470-X"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CRITREVONC.2012.07.006"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTRO.2017.12.002"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.YGYNO.2019.03.260"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.926840\/BIBTEX"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1606\/ASSET\/IMAGES\/G0143F5.JPEG"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS12092678"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.4391"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10147-018-1351-Y\/METRICS"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2075348"},{"key":"e_1_2_13_13_1","unstructured":"FDA HIGHLIGHTS OF PRESCRIBING INFORMATION.These highlights do not include all the information needed to use KEYTRUDA safely and effectively. See full prescribing information for KEYTRUDA. KEYTRUDA\u00ae (pembrolizumab) for injection for intravenous use KEYTRUDA\u00ae (pembrolizumab) injection for intravenous use."},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2112435\/SUPPL_FILE\/NEJMOA2112435_DATA-SHARING.PDF"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.309846\/ASSET\/50CA722F\u201066AC\u2010403F\u2010B396\u20100911869DE20C\/ASSETS\/IMAGES\/LARGE\/709FIG03.JPG"},{"key":"e_1_2_13_16_1","unstructured":"GaffneyDK GaillardS GiuntoliRI GlaserS HolmesJ HowittBE et al.NCCN guidelines version 3.2024 cervical cancer continue NCCN guidelines panel disclosures \u03a9 gynecologic oncology \u00de internal medicine \u2020 medical oncology \u2260 pathology \u00a5 patient advocacy \u00a7 radiotherapy\/radiation oncology *discussion section writing committee.2024."},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.6004\/JNCCN.2023.0062"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/JTH.14246"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-263"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2013-04-460139"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221118370"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/BC800289A"},{"key":"e_1_2_13_23_1","unstructured":"FDA grants accelerated approval to tisotumab vedotin\u2010tftv for recurrent or metastatic cervical cancer | FDA.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010tisotumab\u2010vedotin\u2010tftv\u2010recurrent\u2010or\u2010metastatic\u2010cervical\u2010cancer2024."},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00720"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/S13643-021-01626-4"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.I4919"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.D5928"},{"key":"e_1_2_13_28_1","unstructured":"R: The R Project for Statistical Computing.https:\/\/www.r-project.org\/2024."},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.3102\/10769986030003261"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/SIM.1186"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.2307\/3001666"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/CAS.15443"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00056-5"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30859-3"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2962"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2313811"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLON.2016.10.002"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13778-6"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.3802\/JGO.2017.28.E34"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/IJGC-2019-000880"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2022.910486"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1305810"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1331994"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013348.PUB2"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000001000"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJOC.2023.101979"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1089\/JOP.2015.0064"},{"key":"e_1_2_13_48_1","unstructured":"Tivdak\u00ae (tisotumab vedotin\u2010tftv) | Official patient site.https:\/\/www.tivdak.com\/2024."},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.34507"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1093\/JNCICS\/PKAD069"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/EHJOPEN\/OEAD086"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/CLC.24173"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.16126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T01:51:43Z","timestamp":1739325103000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.16126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,20]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/jog.16126"],"URL":"https:\/\/doi.org\/10.1111\/jog.16126","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,20]]},"assertion":[{"value":"2024-06-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}